Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation
- PMID: 30646564
- PMCID: PMC6356262
- DOI: 10.3390/cells8010047
Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation
Abstract
Adverse outcomes following virus-associated disease in patients receiving allogeneic haematopoietic stem cell transplantation (HSCT) have encouraged strategies to control viral reactivation in immunosuppressed patients. However, despite timely treatment with antiviral medication, some viral infections remain refractory to treatment, which hampers outcomes after HSCT, and are responsible for a high proportion of transplant-related morbidity and mortality. Adoptive transfer of donor-derived lymphocytes aims to improve cellular immunity and to prevent or treat viral diseases after HSCT. Early reports described the feasibility of transferring nonspecific lymphocytes from donors, which led to the development of cell therapy approaches based on virus-specific T cells, allowing a targeted treatment of infections, while limiting adverse events such as graft versus host disease (GvHD). Both expansion and direct selection techniques have yielded comparable results in terms of efficacy (around 70⁻80%), but efficacy is difficult to predict for individual cases. Generating bespoke products for each donor⁻recipient pair can be expensive, and there remains the major obstacle of generating products from seronegative or poorly responsive donors. More recent studies have focused on the feasibility of collecting and infusing partially matched third-party virus-specific T cells, reporting response rates of 60⁻70%. Future development of this approach will involve the broadening of applicability to multiple viruses, the optimization and cost-control of manufacturing, larger multicentred efficacy trials, and finally the creation of cell banks that can provide prompt access to virus-specific cellular product. The aim of this review is to summarise present knowledge on adoptive T cell manufacturing, efficacy and potential future developments.
Keywords: adoptive cell therapy; haematopoietic stem cell transplantation; third party donor; viral infections.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.Cytotherapy. 2015 Oct;17(10):1406-20. doi: 10.1016/j.jcyt.2015.07.005. Cytotherapy. 2015. PMID: 26349000 Clinical Trial.
-
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.Leukemia. 2017 Oct;31(10):2161-2171. doi: 10.1038/leu.2017.16. Epub 2017 Jan 16. Leukemia. 2017. PMID: 28090089 Clinical Trial.
-
Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.J Hematol Oncol. 2017 May 8;10(1):102. doi: 10.1186/s13045-017-0469-0. J Hematol Oncol. 2017. PMID: 28482908 Free PMC article. Clinical Trial.
-
Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.J Hematol Oncol. 2019 Feb 6;12(1):13. doi: 10.1186/s13045-019-0701-1. J Hematol Oncol. 2019. PMID: 30728058 Free PMC article. Review.
-
Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation.Front Immunol. 2020 Oct 15;11:567531. doi: 10.3389/fimmu.2020.567531. eCollection 2020. Front Immunol. 2020. PMID: 33178192 Free PMC article. Review.
Cited by
-
AIM™ platform: A new immunotherapy approach for viral diseases.Front Med (Lausanne). 2022 Dec 23;9:1070529. doi: 10.3389/fmed.2022.1070529. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619639 Free PMC article.
-
In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients.Virusdisease. 2021 Sep;32(3):422-434. doi: 10.1007/s13337-021-00728-w. Epub 2021 Jul 28. Virusdisease. 2021. PMID: 34631973 Free PMC article. Review.
-
Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.Front Immunol. 2021 Dec 23;12:751869. doi: 10.3389/fimmu.2021.751869. eCollection 2021. Front Immunol. 2021. PMID: 35003063 Free PMC article.
-
Reinforcing the Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art.J Fungi (Basel). 2021 Jun 6;7(6):451. doi: 10.3390/jof7060451. J Fungi (Basel). 2021. PMID: 34204025 Free PMC article. Review.
-
Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.Front Immunol. 2021 Aug 19;12:694588. doi: 10.3389/fimmu.2021.694588. eCollection 2021. Front Immunol. 2021. PMID: 34489940 Free PMC article.
References
-
- Hiwarkar P., Gaspar H.B., Gilmour K., Jagani M., Chiesa R., Bennett-Rees N., Breuer J., Rao K., Cale C., Goulden N., et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant. 2013;48:803–808. doi: 10.1038/bmt.2012.221. - DOI - PubMed
-
- Lazzarotto T., Chiereghin A., Piralla A., Piccirilli G., Girello A., Campanini G., Gabrielli L., Costa C., Prete A., Bonifazi F., et al. Cytomegalovirus and Epstein-Barr virus DNA kinetics in whole blood and plasma of allogeneic hematopoietic stem cell transplantation recipients. Biol. Blood Marrow Transplant. 2018;24:1699–1706. doi: 10.1016/j.bbmt.2018.03.005. - DOI - PubMed
-
- Rustia E., Violago L., Jin Z., Foca M.D., Kahn J.M., Arnold S., Sosna J., Bhatia M., Kung A.L., George D., et al. Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, Epstein-Barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2016;22:1646–1653. doi: 10.1016/j.bbmt.2016.05.014. - DOI - PMC - PubMed
-
- Sedláček P., Petterson T., Robin M., Sivaprakasam P., Vainorius E., Brundage T., Chandak A., Mozaffari E., Nichols G., Voigt S. Incidence of adenovirus infection in hematopoietic stem cell transplant recipients: Findings from the AdVance study. Biol. Blood Marrow Transplant. 2018 doi: 10.1016/j.bbmt.2018.12.753. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical